Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
7,125
datasets available to search
ShareScore release 0.7.1
Dataset results
7,125 results for “prostate cancer”
FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer
ClinicalTrials.gov study NCT00917865. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
ClinicalTrials.gov study NCT03732820. IPD Sharing: Not stated. Countries: 17. Publications: 6.
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
ClinicalTrials.gov study NCT02516670. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer
ClinicalTrials.gov study NCT01940276. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
ClinicalTrials.gov study NCT04159896. IPD Sharing: NO. Countries: 1. Publications: 1.
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer
ClinicalTrials.gov study NCT00617669. IPD Sharing: Not stated. Countries: 26. Publications: 1.
68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery
ClinicalTrials.gov study NCT02678351. IPD Sharing: NO. Countries: 1. Publications: 1.
Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
ClinicalTrials.gov study NCT01420965. IPD Sharing: NO. Countries: 1. Publications: 3.
GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere
ClinicalTrials.gov study NCT00274287. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection
ClinicalTrials.gov study NCT02013180. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Functional Outcomes and QoL in Patients With High Versus Low and Intermediate Risk Prostate Cancer Treated by RARP
ClinicalTrials.gov study NCT03790995. IPD Sharing: NO. Countries: 1. Publications: 2.
Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations
ClinicalTrials.gov study NCT03413995. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Single-cell and spatial RNA sequencing identify divergent microenvironments and progression signatures in early- versus late-onset prostate cancer
Open the record for dataset details and reuse information.
Data from: Identification of druggable targets from the interactome of the Androgen Receptor and Serum Response Factor pathways in prostate cancer
Open the record for dataset details and reuse information.
Supplementary material: CYB561 supports the neuroendocrine phenotype in castration-resistant prostate cancer
Open the record for dataset details and reuse information.
YY1 enhances HIF-1α stability in tumor-associated macrophages to suppress anti-tumor immunity of prostate cancer
Open the record for dataset details and reuse information.
Data from: Reinterpretation of prostate cancer pathology by Appl1, Sortilin and Syndecan-1 biomarkers
Open the record for dataset details and reuse information.
Data from: Probabilistic interfractional motion carbon ion radiation therapy dose distribution for prostate cancer shows rectum sparing with moderate target coverage degradation
Purpose: This observational study investigates the influence of interfractional motion on clinical target volume (CTV) coverage, planning target volume (PTV) margins, and rectum tissue sparing in carbon ion radiation therapy (CIRT). It reports dose coverage to target structures and organs at risk in the presence of interfractional motion, investigates rectal tissue sparing, and provides recommendations for further lowering the rate of toxicity. We also propose probabilistic DVH for consideration in treatment planning to represent probable dose to the clinic's patient population. Methods: At Gunma University Hospital intensity-modulated x-ray therapy (IMXT, aka IMRT) prostate cancer patients are positioned on a table which is shifted twice based on cone-beam computed tomography (CBCT) to align bones and then align prostate tissue to isocenter. These shifts thereby contain interfractional motion. 1306 such tableshifts from 85 patients were collected. Normal probability distributions were fit to the difference between bone-matching and prostate-matching CBCT-to-planning CT tableshifts (i.e. interfractional motion). Between 2011 and 2016 CIRT prostate patients were treated with PTV1 and PTV2 margins as follows: PTV1 extends the prostate contour by 10/10, 5/10, 6/6 mm in the right/left, posterior/anterior, and superior/inferior directions, respectively, and the proximal seminal vesicles contour by 5 mm superiorly and inferiorly, 3 mm right and left. PTV2 reduces PTV1 posteriorly along a straight line to exclude the rectum and reduces the superior and inferior margins by 6 mm. From those treated with these margins, 40 patients' beam data were selected to create probable interfractional motion: The previously fit normal probability distributions were randomly sampled 2000 times per patient and beams shifted to simulate this motion. These shifted dose distributions were scaled down proportionately in magnitude and summed to obtain probable blurred dose distributions. Results: Probable dose to rectum is substantially less than planned for doses higher than 10 Gy(RBE). Absolute DVH show that mean clinical target volumes are about 138-670 cm3 smaller for a given probable dose than planned doses higher than 57 Gy(RBE) after accounting for standard error. Cumulative DVH show mean CTV fraction receiving a given probable dose is less than the mean fraction receiving the corresponding planned dose for doses larger than 52 Gy(RBE), up to 19% less at 57.4 Gy(RBE). Our PTV1 margins generally cover 95% of interfractional motion but seminal vesicles and inferior prostate receive less dose than planned due to insufficient PTV2 margins. Conclusion: Assuming rigidly shifting interfractional motion around the prostate region and neglecting minor changes in soft tissue stopping power, interfractional motion resulted in underdosing or tissue sparing in all cases. Given our low rates of relapse and recurrence, it appears less curative dose is needed than previously thought or else the target may be smaller than previously thought. In-room CT may be useful to lower dose, shrink target margins, conduct PET auto-activation dose verification studies and account for interfractional motion.
cis-mQTL results in prostate cancer tissue of European ancestry patients and African ancestry patients
<p>cis-mQTL results of in tumor tissues</p>
Data used in "Biologically informed deep neural network for prostate cancer discovery" publication
<p>Data used in the publication titled "<strong>Biologically informed deep neural network for prostate cancer discovery </strong>" </p> <p>Elmarakeby, Haitham A., et al. "Biologically informed deep neural network for prostate cancer discovery." <em>Nature</em> 598.7880 (2021): 348-352.</p> <p>These datasets were derived from the following public domain resources:</p> <ol> <li>Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018;50: 645–651. DOI: <a href="https://doi.org/10.1038/s41588-018-0078-z">10.1038/s41588-018-0078-z</a></li> <li>Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature. 2017;541: 359–364. https://doi.org/10.1038/nature20788</li> <li>Robinson DR, Wu Y-M, Lonigro RJ, Vats P, Cobain E, Everett J, et al. Integrative clinical genomics of metastatic cancer. Nature. 2017;548: 297–303. https://doi.org/10.1038/nature23306</li> <li>Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, et al. The Reactome Pathway Knowledgebase. Nucleic Acids Res. 2018;46: D649–D655. DOI: <a href="https://doi.org/10.1093/nar/gkv1351">10.1093/nar/gkv1351</a></li> </ol> <p> </p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.